Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01458210 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01458210 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 22 participants.
The verdict
NCT01458210, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to look at how the body processes oral contraceptive (OC), using Ortho-Cyclen, as a commonly prescribed combination oral contraceptive in healthy female participants, and the effect of dulaglutide on how Ortho-Cyclen is processed by the body. Information about any side effects that may occur will also be collected.
Interventions
- BIOLOGICAL Dulaglutide
- DRUG Ortho-Cyclen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01458210
The ClinicalTrials.gov registry entry for NCT01458210 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dulaglutide is the first listed.
NCT01458210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01458210 about?
NCT01458210 is a clinical study titled "A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants". The purpose of this study is to look at how the body processes oral contraceptive (OC), using Ortho-Cyclen, as a commonly prescribed combination oral contraceptive in healthy female participants, and the effect of dulaglutide on how Ortho-Cyclen is processed by the body. Information about any side e...
What is the current status of trial NCT01458210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-10. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01458210?
The interventions under investigation include: Dulaglutide (BIOLOGICAL), Ortho-Cyclen (DRUG).
Who is sponsoring clinical trial NCT01458210?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.